LLY is trading 3.1% up today at $1018.76, recovering from a previous session sell-off triggered by concerns over potential expansions to discounted drug programs.
- The move marks a company-specific recovery as investors shift focus back to the long-term strength of Lilly’s obesity and diabetes drug portfolio.
- The stock is showing resilience despite broader market weakness and risk-off sentiment across major indices.
- Market participants appear to be reassessing the actual policy impact, moving past the initial pricing headline shock seen on Monday.